Table 5. Known Estrogenic and Nonestrogenic Compoundsa.
| AC50s
(μM) |
||||
|---|---|---|---|---|
| relative potency | chemical name | bER | hER | mERa |
| inactive | atrazine | 0 | 0 | 0 |
| inactive | linuron | 0 | 0 | 0 |
| inactive | haloperidol | 0 | 0 | 0 |
| inactive | phenobarbital sodium salt | 0 | 0 | 0 |
| inactive | progesterone | 0 | 0 | 0 |
| inactive | ketoconazole | 0 | 0 | 0 |
| inactive summary | 100% | 100% | 100% | |
| very weak | ethylparaben | 0 | 0 | 0 |
| very weak | methoxychlor | 0 | 0 | 0 |
| very weak | butyl benzyl phthalate | 0 | 0 | 0 |
| very weak summary | 0% | 0% | 0% | |
| weak | 4-(1,1,3,3-tetramethylbutyl)phenol | 33.000 | 7.200 | 8.200 |
| weak | kepone | 0 | 0 | 0 |
| weak | genistein | 0.130 | 0.032 | 0.130 |
| weak | 4-cumylphenol | 16.000 | 0 | 12.000 |
| weak | bisphenol B | 0.430 | 0.300 | 0.023 |
| weak | o,p-DDT | 0 | 0 | 0 |
| weak | bisphenol A | 0.630 | 0.820 | 1.100 |
| weak | 4-nonylphenol, branched | 33.000 | 20.000 | 5.600 |
| weak | butylparaben | 56.999 | 17.000 | 23.000 |
| weak summary | 78% | 67% | 78% | |
| strong | 17β-estradiol | 0.023 | 0.023 | 0.023 |
| strong | diethylstilbestrol | 0.023 | 0.023 | 0.023 |
| strong | 17α-ethinylestradiol | 0.023 | 0.023 | 0.023 |
| strong summary | 100% | 100% | 100% | |
| antagonist | tamoxifen | 0.100 | 0.330 | 0.200 |
| antagonist summary | 100% | 100% | 100% | |
a
The chemicals are listed along with their relative potency for the estrogen receptor (as noted within the EPA’s Endocrine Disruptor Screening Program) and calculated AC50 values for the three estrogen assays. The summary for each potency category indicates the percent of chemical–AC50 combinations that were correctly identified in the HTS.